T2 Biosystems

T2 Biosystems Inc is a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes. It is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. The company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance technology.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGRI

AIRE

AMBC

AUDC

FGEN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HSDT

NUVO

PLTN

PLTR

TCBP

TRUP

TTOO

ZETA

Why Zeta Global Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket

Intraday Update

ABEO

AZTR

CALX

CDTX

CHCI

CSLR

CTCX

FCEL

GWAV

HIBB

HRTX

HSTM

JAGX

JBLU

KULR

LICN

MESO

MLEC

MSCI

OPRT

PALI

PEGY

PHIO

RNAC

ROKU

SMFL

SMXT

SPCB

SPCE

SPOT

TIRX

TRSG

YYGH

Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Hibbett - logo

AGBA

CDNS

CHNR

IBRX

NUWE

TOVX

Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket

T2 Biosystems Inc

Health Care

Press Releases

T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens

T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform

T2 Biosystems to Host Business Update Call on October 10, 2024

T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024

Earnings

T2 Biosystems Announces Third Quarter 2024 Financial Results

T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens

Contracts

T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.

General

T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally

T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Canaccord Genuity

Alliance Global Partners

Comments

T2 Biosystems

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell